Resminostat

Resminostat is an orally administered small molecule inhibitor of histone deacetylases (HDACs), specifically targeting class I (HDAC1, HDAC2, HDAC3, HDAC8), class IIb (HDAC6, HDAC10), and class IV (HDAC11) enzymes[3][6][7]. By inhibiting these enzymes, resminostat induces hyperacetylation of histones and non-histone proteins such as α-tubulin. This leads to chromatin remodeling, inhibition of tumor suppressor gene transcription repression, cell cycle arrest via upregulation of p21 protein, and ultimately apoptosis in cancer cells[3][4][6][8]. Resminostat has demonstrated anti-proliferative effects across a broad range of cancer cell types including hepatocellular carcinoma (HCC), cutaneous T-cell lymphoma (CTCL), multiple myeloma, Hodgkin's lymphoma, and head and neck squamous cell carcinoma[2][3][4][5]. It is being developed by 4SC for oncology indications in Europe and by Yakult Honsha in Japan[7].

Brand names

Kinselby

Other names

864814-88-0